Have a feature idea you'd love to see implemented?
Let us know!
SGMT Sagimet Biosciences Inc
Price (delayed)
$4.5
Market cap
$144.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.59
Enterprise value
$67.98M
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid,
Highlights
The quick ratio has surged by 85% year-on-year and by 28% since the previous quarter
The EPS has soared by 97% YoY but it has decreased by 2.9% from the previous quarter
The equity has soared by 74% year-on-year but it has declined by 7% since the previous quarter
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Sagimet Biosciences's gross profit has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of SGMT
Market
Valuations
Earnings
Shares outstanding
32.2M
Market cap
$144.88M
Enterprise value
$67.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.85
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$37.52M
EBITDA
-$37.37M
Free cash flow
-$38.49M
Per share
Balance sheet
Liquidity
EPS
-$3.59
Free cash flow per share
-$1.2
Book value per share
$5.3
Revenue per share
$0
TBVPS
$5.44
Total assets
$174.78M
Total liabilities
$4.09M
Debt
$116,000
Equity
$170.68M
Working capital
$153.1M
Debt to equity
0
Current ratio
38.41
Quick ratio
37.26
Net debt/EBITDA
2.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-22.9%
Return on equity
-23.6%
Return on invested capital
-71.3%
Return on capital employed
-22%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SGMT stock price
How has the Sagimet Biosciences stock price performed over time
Intraday
-0.44%
1 week
-13.13%
1 month
-19.21%
1 year
38.89%
YTD
-16.97%
QTD
62.45%
Financial performance
How have Sagimet Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.73M
Net income
-$37.52M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Sagimet Biosciences's gross profit has shrunk by 100% QoQ and by 100% YoY
SGMT's operating income has shrunk by 60% YoY and by 26% QoQ
The net income has declined by 39% year-on-year and by 28% since the previous quarter
Growth
What is Sagimet Biosciences's growth rate over time
Valuation
What is Sagimet Biosciences stock price valuation
P/E
N/A
P/B
0.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 97% YoY but it has decreased by 2.9% from the previous quarter
The equity has soared by 74% year-on-year but it has declined by 7% since the previous quarter
SGMT's price to book (P/B) is 6% higher than its last 4 quarters average of 0.8
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Efficiency
How efficient is Sagimet Biosciences business performance
The return on invested capital has surged by 79% year-on-year and by 31% since the previous quarter
Sagimet Biosciences's return on assets has surged by 61% YoY but it has decreased by 14% QoQ
The company's return on equity fell by 13% QoQ
Dividends
What is SGMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SGMT.
Financial health
How did Sagimet Biosciences financials performed over time
Sagimet Biosciences's current ratio has surged by 89% YoY and by 32% QoQ
The quick ratio has surged by 85% year-on-year and by 28% since the previous quarter
The debt is 100% less than the equity
The equity has soared by 74% year-on-year but it has declined by 7% since the previous quarter
The debt has contracted by 24% from the previous quarter but it has grown by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.